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The last European Society of Cardiology guidelines have assigned a class IIa (level of evidence B) recommendation to percutaneous coronary interventions of chronic total occlusions (CTO PCI) in patients with expected ischemia reduction in a corresponding myocardial territory and/or angina relief. 1 However, comprehensive information in this field has been limited and conclusive evidence that could be applied in clinical practice seems to be lacking. In this edition of Angiology, Eyuboglu and Ozkurt 2 cautioned with good reason against the routine use of CTO PCI as it may not prove useful and may even be harmful in most cases. Instead, they recommended PCI only in accurately selected patients.
Recently acquired scientific data have shed more light on this controversial issue. Al-Lamee et al 3 showed that PCI of the nonoccluded lesions, as the initial management strategy in stable patients, did not reduce the risk of major adverse coronary events (MACEs) when added to optimal medical therapy (OMT). Similarly, CTO PCI might not show an overall benefit in terms of MACE reduction of myocardial contractility improvement as compared to OMT 4 months to 3 years after successful revascularization. [4] [5] [6] [7] Optimal medical therapy alone proved particularly effective in patients with low SYNTAX ( 12) and APPROACH scores ( 18). 5 In contrast, CTO PCI appeared better to relieve ischemic symptoms 7 and was superior to OMT if the left anterior descending artery was involved. 4 Unfortunately, high treatment crossover rates were observed in medication-only groups, particularly when patients acknowledged that a significant coronary obstruction had not been stented. 3 Finally, we have learned from previous studies that large ( 10%) areas of the ischemic myocardium carried an increased risk of cardiovascular death or myocardial infarction (MI), whereas absence of the viable myocardium was associated with no significant difference in outcomes, irrespective of treatment strategy. 8 In a previous issue of Angiology, we presented our experience with stable patients in whom a complete coronary revascularization (CCR) was percutaneously achieved. 9 Our study was a single-center registry analysis with related pitfalls and, as such, adequately mirrored the real-world situation. We enrolled 465 patients assigned into 3 groups (group 1: successful CTO PCI, group 2: failed CTO PCI, and group 3: successful non-CTO PCI). More than 97% patients in both CTO groups were symptomatic and perfusion scintigraphy was available in 45% of them. Single-vessel CTO PCI was attempted as the final stage procedure to achieve CCR in most (> 70%) patients; at that point, it seemed unrealistic to offer them randomization into PCI plus OMT or OMT alone. We were fully aware that comparing successful and failed CTO PCI did not provide a conclusive evidence of the efficacy of PCI compared with other forms of treatment. 10 The follow-up extended up to 5 years. At the end of the survey, group 2 patients, for example, were taking antiplatelet drugs in 97.6%, anti-ischemic drugs in 87.5%, and statins in 79.9%. Major adverse coronary event composite (cardiovascular mortality, nonfatal MI, unplanned target vessel revascularization, and stent thrombosis), the main end point of the study, occurred more frequently in group 2 (29.5% vs 4.8% in group 1 vs 3.5% in group 3, P ¼ .0001); inhospital events were not taken into account. We assumed that (1) long-term outcomes of patients with stable coronary artery disease (CAD), in whom the CCR had been percutaneously achieved, seemed comparable to patients with nonobstructive CAD; (2) clinical benefits of the CCR were similarly maintained after successful CTO as well as non-CTO PCI; and (3) failed CTO PCI was associated with increased rates of MACE, such as recurrent symptoms and unplanned target vessel revascularization.
In conclusion, OMT should be started as the initial treatment in all patients with obstructive CAD. As pointed out by Eyuboglu and Ozkurt, 2 patients with CTO should better be riskstratified, based on symptoms, coronary anatomy, and extent of ischemia/viability, before any revascularization attempt. A safe and effective CTO PCI should be offered to those with highrisk features. Finally, CCR should be the ultimate revascularization goal in patients with obstructive CAD.
